VAG
SLNO

VisionPoint Advisory Group’s Soleno Therapeutics SLNO Stock Holding History

VisionPoint Advisory Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-168
Closed -$6.85K – 685
2024
Q2 		$6.85K Hold
168
– – ﹤0.01% 523
2024
Q1 		$7.19K Hold
168
– – ﹤0.01% 495
2023
Q4 		$6.76K Hold
168
– – ﹤0.01% 458
2023
Q3 		$4.96K Hold
168
– – ﹤0.01% 499
2023
Q2 		$721 Buy
+168
New +$722 ﹤0.01% 514

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VisionPoint Advisory Group's SLNO Position: Q3 2024 in Review

VisionPoint Advisory Group sold out of Soleno Therapeutics (SLNO) in Q3 2024, closing a stake of 168 shares — an estimated $6.85K sold.

VisionPoint Advisory Group first reported a position in SLNO in Q2 2023 and held it in 5 quarters. The position peaked at $7.19K in Q1 2024. 142 funds tracked by Wall St. Rank hold SLNO as of Q3 2024.

  • VisionPoint Advisory Group reported no remaining Soleno Therapeutics position as of Q3 2024 after selling out during the quarter.
  • VisionPoint Advisory Group sold 168 Soleno Therapeutics shares in Q3 2024, an estimated $6.85K.
  • VisionPoint Advisory Group first reported a position in Soleno Therapeutics in Q2 2023 and held it in 5 quarters.
  • VisionPoint Advisory Group's Soleno Therapeutics position peaked at $7.19K in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2024.

Based on VisionPoint Advisory Group's 13F filing for Q3 2024, filed 15 Oct 2024.